574 related articles for article (PubMed ID: 29118225)
21. [Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
Delaye M; Rodrigues M
Bull Cancer; 2020 Nov; 107(11):1085-1086. PubMed ID: 33169692
[No Abstract] [Full Text] [Related]
22. NTRK-Rearranged soft tissue neoplasms: A review of evolving diagnostic entities and algorithmic detection methods.
Surrey LF; Davis JL
Cancer Genet; 2022 Jan; 260-261():6-13. PubMed ID: 34794069
[TBL] [Abstract][Full Text] [Related]
23. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
[TBL] [Abstract][Full Text] [Related]
24. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
Marchiò C; Scaltriti M; Ladanyi M; Iafrate AJ; Bibeau F; Dietel M; Hechtman JF; Troiani T; López-Rios F; Douillard JY; Andrè F; Reis-Filho JS
Ann Oncol; 2019 Sep; 30(9):1417-1427. PubMed ID: 31268127
[TBL] [Abstract][Full Text] [Related]
25. Tropomyosin receptor kinase inhibitors in the management of sarcomas.
Wilding CP; Loong HH; Huang PH; Jones RL
Curr Opin Oncol; 2020 Jul; 32(4):307-313. PubMed ID: 32541318
[TBL] [Abstract][Full Text] [Related]
26. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract][Full Text] [Related]
27. TRK inhibitors in TRK fusion-positive cancers.
Drilon A
Ann Oncol; 2019 Nov; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426
[TBL] [Abstract][Full Text] [Related]
28. Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib.
Florou V; Nevala-Plagemann C; Whisenant J; Maeda P; Gilcrease GW; Garrido-Laguna I
J Natl Compr Canc Netw; 2021 May; 19(5):478-482. PubMed ID: 34030125
[TBL] [Abstract][Full Text] [Related]
29. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Desai AV; Robinson GW; Gauvain K; Basu EM; Macy ME; Maese L; Whipple NS; Sabnis AJ; Foster JH; Shusterman S; Yoon J; Weiss BD; Abdelbaki MS; Armstrong AE; Cash T; Pratilas CA; Corradini N; Marshall LV; Farid-Kapadia M; Chohan S; Devlin C; Meneses-Lorente G; Cardenas A; Hutchinson KE; Bergthold G; Caron H; Chow Maneval E; Gajjar A; Fox E
Neuro Oncol; 2022 Oct; 24(10):1776-1789. PubMed ID: 35395680
[TBL] [Abstract][Full Text] [Related]
30. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
Rohrberg KS; Lassen U
Drugs; 2021 Mar; 81(4):445-452. PubMed ID: 33400240
[TBL] [Abstract][Full Text] [Related]
31. Emerging Targeted Therapy for Tumors with
Kheder ES; Hong DS
Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
[TBL] [Abstract][Full Text] [Related]
32. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
Drilon A; Li G; Dogan S; Gounder M; Shen R; Arcila M; Wang L; Hyman DM; Hechtman J; Wei G; Cam NR; Christiansen J; Luo D; Maneval EC; Bauer T; Patel M; Liu SV; Ou SH; Farago A; Shaw A; Shoemaker RF; Lim J; Hornby Z; Multani P; Ladanyi M; Berger M; Katabi N; Ghossein R; Ho AL
Ann Oncol; 2016 May; 27(5):920-6. PubMed ID: 26884591
[TBL] [Abstract][Full Text] [Related]
33. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
[TBL] [Abstract][Full Text] [Related]
34. Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.
Joshi SK; Qian K; Bisson WH; Watanabe-Smith K; Huang A; Bottomly D; Traer E; Tyner JW; McWeeney SK; Davare MA; Druker BJ; Tognon CE
Blood; 2020 Jun; 135(24):2159-2170. PubMed ID: 32315394
[TBL] [Abstract][Full Text] [Related]
35. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA
Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294
[TBL] [Abstract][Full Text] [Related]
36. The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
Blauel ER; Laetsch TW
Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663
[TBL] [Abstract][Full Text] [Related]
37. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
Hibar DP; Demetri GD; Peters S; Davies J; Humblet O; Maund SL; Perez L
PLoS One; 2022; 17(8):e0270571. PubMed ID: 35939431
[TBL] [Abstract][Full Text] [Related]
38. New targets bring hope in squamous cell lung cancer: neurotrophic tyrosine kinase gene fusions.
Rolfo C; Raez L
Lab Invest; 2017 Nov; 97(11):1268-1270. PubMed ID: 29085074
[TBL] [Abstract][Full Text] [Related]
39. TRK inhibition in soft tissue sarcomas: A comprehensive review.
Assi T; Rassy E; Nassereddine H; Farhat F; Karak FE; Kattan J; Ghosn M
Semin Oncol; 2020 Feb; 47(1):73-84. PubMed ID: 32201016
[TBL] [Abstract][Full Text] [Related]
40. [Mid gut neuroendocrine tumors: News on medical treatment].
Dior M; Dreanic J; Prieux-Klotz C; Brieau B; Brezault C; Coriat R
Presse Med; 2017 Jan; 46(1):4-10. PubMed ID: 28089247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]